Within-subject biological variation estimated using real-world data strategies (RWD): a systematic review.

IF 6.6 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY
Fernando Marques-García, Ana Nieto-Librero, Xavier Tejedor-Ganduxe, Cristina Martinez-Bravo
{"title":"Within-subject biological variation estimated using real-world data strategies (RWD): a systematic review.","authors":"Fernando Marques-García, Ana Nieto-Librero, Xavier Tejedor-Ganduxe, Cristina Martinez-Bravo","doi":"10.1080/10408363.2025.2464244","DOIUrl":null,"url":null,"abstract":"<p><p>Biological variation (BV) is defined as the variation in the concentration of a measurand around the homeostatic set point. This is a concept introduced by Fraser and Harris in the second part of the twentieth century. BV is divided into two different estimates: within-subject BV (CV<sub>I</sub>) and between-subject BV (CV<sub>G</sub>). Biological variation studies of biomarkers have been gaining importance in recent years due to the potential practical application of these estimates. The main applications of BV in the clinical laboratory include: the establishment of Analytical Performance Specifications (APS), estimation of the individual's homeostatic set point (HSP), calculation of Reference Change Value (RCV), estimation of individuality index calculation (II), and establishment of personalized reference intervals (prRI). The classic models for obtaining BV estimates have been the most used to date. In these studies, a target population (\"normal\" population), a sampling frequency and time, and a number of samples per individual, among other factors, are defined. The Biological Variation Data Critical Appraisal Checklist (BIVAC) established by the Task Group-Biological Variation Database (TG-BVD) of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) represents a guide for the evaluation and performance of these direct studies. These methods have limitations because they are laborious, expensive, invasive, and are based on an ideal population. In recent years, models have been proposed to obtain BV estimates based on the Real-World Data (RWD) strategy. In this case, we move from a model with a low number of individuals (direct methods) to a population model using the data stored in the Laboratory Information System (LIS). RWD methods are presented as an alternative to overcome the limitations of direct methods. Currently, there is little scientific evidence on the application of RWD models since only five papers have been published. In these papers, three different working algorithms are proposed (Loh et al., Jones et al., and Marques-Garcia et al.). These algorithms are divided into three fundamental stages for their development: patient data and study design, database(s) cleaning, and statistical strategies for obtaining BV estimates. When working with large amounts of data, RWD methods allow us to subdivide the population and thus obtain estimates into subgroups, what would be more difficult using direct methods. Of the three algorithms proposed, the algorithm developed in the Spanish multicenter project <i>BiVaBiDa</i> is the most complete, as it overcomes the limitations of the other two, including the possibility of calculating the confidence interval of the BV estimate. RWD methods also have limitations such as the anonymization of data and the standardization of electronic medical records, as well as the statistical complexity associated with data analysis. It is necessary to continue working on the development of RWD algorithms that allow us to obtain BV estimates that, which are as robust as possible.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":" ","pages":"1-13"},"PeriodicalIF":6.6000,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in clinical laboratory sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10408363.2025.2464244","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Biological variation (BV) is defined as the variation in the concentration of a measurand around the homeostatic set point. This is a concept introduced by Fraser and Harris in the second part of the twentieth century. BV is divided into two different estimates: within-subject BV (CVI) and between-subject BV (CVG). Biological variation studies of biomarkers have been gaining importance in recent years due to the potential practical application of these estimates. The main applications of BV in the clinical laboratory include: the establishment of Analytical Performance Specifications (APS), estimation of the individual's homeostatic set point (HSP), calculation of Reference Change Value (RCV), estimation of individuality index calculation (II), and establishment of personalized reference intervals (prRI). The classic models for obtaining BV estimates have been the most used to date. In these studies, a target population ("normal" population), a sampling frequency and time, and a number of samples per individual, among other factors, are defined. The Biological Variation Data Critical Appraisal Checklist (BIVAC) established by the Task Group-Biological Variation Database (TG-BVD) of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) represents a guide for the evaluation and performance of these direct studies. These methods have limitations because they are laborious, expensive, invasive, and are based on an ideal population. In recent years, models have been proposed to obtain BV estimates based on the Real-World Data (RWD) strategy. In this case, we move from a model with a low number of individuals (direct methods) to a population model using the data stored in the Laboratory Information System (LIS). RWD methods are presented as an alternative to overcome the limitations of direct methods. Currently, there is little scientific evidence on the application of RWD models since only five papers have been published. In these papers, three different working algorithms are proposed (Loh et al., Jones et al., and Marques-Garcia et al.). These algorithms are divided into three fundamental stages for their development: patient data and study design, database(s) cleaning, and statistical strategies for obtaining BV estimates. When working with large amounts of data, RWD methods allow us to subdivide the population and thus obtain estimates into subgroups, what would be more difficult using direct methods. Of the three algorithms proposed, the algorithm developed in the Spanish multicenter project BiVaBiDa is the most complete, as it overcomes the limitations of the other two, including the possibility of calculating the confidence interval of the BV estimate. RWD methods also have limitations such as the anonymization of data and the standardization of electronic medical records, as well as the statistical complexity associated with data analysis. It is necessary to continue working on the development of RWD algorithms that allow us to obtain BV estimates that, which are as robust as possible.

使用真实世界数据策略(RWD)估计受试者内生物变异:系统综述。
生物变异(Biological variation, BV)被定义为测量物浓度在稳态设定值附近的变化。这是弗雷泽和哈里斯在20世纪下半叶提出的概念。BV分为两种不同的估计:受试者内BV (CVI)和受试者间BV (CVG)。近年来,由于这些估计的潜在实际应用,生物标志物的生物变异研究变得越来越重要。BV在临床实验室的主要应用包括:建立分析性能规范(APS),估计个体的稳态设定点(HSP),计算参考变化值(RCV),估计个性指数计算(II),建立个性化参考区间(prRI)。获得BV估计的经典模型是迄今为止使用最多的。在这些研究中,定义了目标人群(“正常”人群),采样频率和时间,以及每个人的样本数量,以及其他因素。由欧洲临床化学和检验医学联合会(EFLM)的生物变异数据库(TG-BVD)任务组建立的生物变异数据关键评估清单(BIVAC)代表了这些直接研究的评估和表现指南。这些方法有局限性,因为它们费力、昂贵、侵入性强,而且是基于理想人群。近年来,人们提出了基于真实世界数据(Real-World Data, RWD)策略的BV估计模型。在这种情况下,我们从个体数量较少的模型(直接方法)转移到使用存储在实验室信息系统(LIS)中的数据的总体模型。RWD方法是克服直接方法局限性的一种替代方法。目前,关于RWD模型应用的科学证据很少,仅发表了5篇论文。在这些论文中,提出了三种不同的工作算法(Loh等人,Jones等人,和Marques-Garcia等人)。这些算法的发展分为三个基本阶段:患者数据和研究设计、数据库清理和获得BV估计的统计策略。当处理大量数据时,RWD方法允许我们对总体进行细分,从而获得子组的估计值,而使用直接方法则更加困难。在提出的三种算法中,西班牙多中心项目BiVaBiDa开发的算法是最完整的,因为它克服了其他两种算法的局限性,包括计算BV估计的置信区间的可能性。RWD方法也有局限性,例如数据的匿名化和电子医疗记录的标准化,以及与数据分析相关的统计复杂性。有必要继续致力于RWD算法的开发,使我们能够获得尽可能鲁棒的BV估计。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
20.00
自引率
0.00%
发文量
25
审稿时长
>12 weeks
期刊介绍: Critical Reviews in Clinical Laboratory Sciences publishes comprehensive and high quality review articles in all areas of clinical laboratory science, including clinical biochemistry, hematology, microbiology, pathology, transfusion medicine, genetics, immunology and molecular diagnostics. The reviews critically evaluate the status of current issues in the selected areas, with a focus on clinical laboratory diagnostics and latest advances. The adjective “critical” implies a balanced synthesis of results and conclusions that are frequently contradictory and controversial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信